Lenvatinib (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Lenvatinib" in English language version.

refsWebsite

Global rank English rank

3europa.eu

68^th place

117^th place

3fda.gov

447^th place

338^th place

2doi.org

2^nd place

2nih.gov

4^th place

2web.archive.org

1^st place

1tga.gov.au

3,984^th place

2,622^nd place

1canada.ca

1,712^th place

1,063^rd place

1drugs.com

399^th place

333^rd place

1semanticscholar.org

11^th place

8^th place

1asco.org

low place

1clinicaltrials.gov

5,225^th place

4,062^nd place

1eisai.com

low place

asco.org

Glen H, Boss D, Evans TR, Roelvink M, et al. (2007). "A phase I dose finding study of E7080 in patients (pts) with advanced malignancies". Journal of Clinical Oncology, ASCO Annual Meeting Proceedings Part I. 25 (18S): 14073. Archived from the original on 2012-02-24. Retrieved 2009-09-02.

canada.ca

"Health Canada New Drug Authorizations: 2015 Highlights". Health Canada. 4 May 2016. Retrieved 7 April 2024.

clinicaltrials.gov

Clinical trial number NCT01321554 for "A Trial of E7080 in 131I-Refractory Differentiated Thyroid Cancer" at ClinicalTrials.gov

doi.org

Matsui J, Funahashi Y, Uenaka T, Watanabe T, Tsuruoka A, Asada M (September 2008). "Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase". Clinical Cancer Research. 14 (17): 5459–65. doi:10.1158/1078-0432.CCR-07-5270. PMID 18765537.
Inoue K, Mizuo H, Kawaguchi S, Fukuda K, Kusano K, Yoshimura T (August 2014). "Oxidative metabolic pathway of lenvatinib mediated by aldehyde oxidase". Drug Metabolism and Disposition. 42 (8): 1326–33. doi:10.1124/dmd.114.058073. PMID 24914245. S2CID 206497491.

drugs.com

FDA Professional Drug Information for Lenvima.

eisai.com

"Phase III trial shows lenvatinib meets primary endpoint of progression free survival benefit in treatment of radioiodine-refractory differentiated thyroid cancer" (PDF). Eisai. 3 February 2014.

europa.eu

ema.europa.eu

"Kisplyx EPAR". European Medicines Agency. 25 August 2016. Retrieved 7 January 2024.
"Lenvima". European Medicines Agency. 2015-05-28.
"Summary of the European public assessment report (EPAR) for Lenvima". European Medicines Agency. 17 September 2018. Archived from the original on 20 June 2018. Retrieved 9 January 2016.

fda.gov

"Lenvatinib in combination with Everolimus". U.S. Food and Drug Administration (FDA). 16 May 2016.
"FDA approves lenvatinib for unresectable hepatocellular carcinoma". U.S. Food and Drug Administration (FDA). 16 August 2018. Retrieved 2018-08-16.
U.S. Food and Drug Administration. Hematology/Oncology (Cancer) Approvals & Safety Notifications. [1]

nih.gov

pubmed.ncbi.nlm.nih.gov

Matsui J, Funahashi Y, Uenaka T, Watanabe T, Tsuruoka A, Asada M (September 2008). "Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase". Clinical Cancer Research. 14 (17): 5459–65. doi:10.1158/1078-0432.CCR-07-5270. PMID 18765537.
Inoue K, Mizuo H, Kawaguchi S, Fukuda K, Kusano K, Yoshimura T (August 2014). "Oxidative metabolic pathway of lenvatinib mediated by aldehyde oxidase". Drug Metabolism and Disposition. 42 (8): 1326–33. doi:10.1124/dmd.114.058073. PMID 24914245. S2CID 206497491.

semanticscholar.org

api.semanticscholar.org

Inoue K, Mizuo H, Kawaguchi S, Fukuda K, Kusano K, Yoshimura T (August 2014). "Oxidative metabolic pathway of lenvatinib mediated by aldehyde oxidase". Drug Metabolism and Disposition. 42 (8): 1326–33. doi:10.1124/dmd.114.058073. PMID 24914245. S2CID 206497491.

tga.gov.au

"Prescription medicines: registration of new chemical entities in Australia, 2016". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.

web.archive.org

Glen H, Boss D, Evans TR, Roelvink M, et al. (2007). "A phase I dose finding study of E7080 in patients (pts) with advanced malignancies". Journal of Clinical Oncology, ASCO Annual Meeting Proceedings Part I. 25 (18S): 14073. Archived from the original on 2012-02-24. Retrieved 2009-09-02.
"Summary of the European public assessment report (EPAR) for Lenvima". European Medicines Agency. 17 September 2018. Archived from the original on 20 June 2018. Retrieved 9 January 2016.